Department of Clinical Biochemistry and Applied Cell Science, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran.
Department of Biotechnology, College of Science, University of Tehran, Tehran, Iran.
Stem Cell Rev Rep. 2020 Jun;16(3):427-433. doi: 10.1007/s12015-020-09973-w.
"COVID-19" is the word that certainly isn't forgotten by everybody who lives in the first half of the twenty-first century. COVID-19, as a pandemic, has led many researchers from different biomedical fields to find solutions or treatments to manage the pandemic. However, no standard treatment for this disease has been discovered to date. Probably, preventing the severe acute respiratory infection form of COVID-19 as the most dangerous phase of this disease can be helpful for the treatment and reduction of the death rate. In this regard, mesenchymal stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach and several clinical trials have begun. Recently, MSCs according to their immunomodulatory and regenerative properties attract attention in clinical trials. After the intravenous transplantation of MSCs, a significant population of cells accumulates in the lung, which they alongside immunomodulatory effect could protect alveolar epithelial cells, reclaim the pulmonary microenvironment, prevent pulmonary fibrosis, and cure lung dysfunction. Given the uncertainties in this area, we reviewed reported clinical trials and hypotheses to provide useful information to researchers and those interested in stem cell therapy. In this study, we considered this new approach to improve patient's immunological responses to COVID-19 using MSCs and discussed the aspects of this proposed treatment. However, currently, there are no approved MSC-based approaches for the prevention and/or treatment of COVID-19 patients but clinical trials ongoing.
“COVID-19”这个词无疑是 21 世纪上半叶每一个人都不会忘记的。COVID-19 作为一种大流行疾病，促使许多来自不同生物医学领域的研究人员寻找解决方案或治疗方法来管理这一大流行。然而，迄今为止，尚未发现针对这种疾病的标准治疗方法。或许，预防 COVID-19 的严重急性呼吸道感染形式作为这种疾病最危险的阶段，可以有助于治疗和降低死亡率。在这方面，基于间充质干细胞（MSCs）的免疫调节治疗已被提议为一种合适的治疗方法，并且已经开始了几项临床试验。最近，MSCs 因其免疫调节和再生特性而在临床试验中受到关注。在静脉内移植 MSCs 后，大量细胞会积聚在肺部，它们通过免疫调节作用可以保护肺泡上皮细胞、恢复肺微环境、预防肺纤维化和治愈肺功能障碍。鉴于这方面的不确定性，我们回顾了已报道的临床试验和假设，为研究人员和对干细胞治疗感兴趣的人提供了有用的信息。在这项研究中，我们考虑了使用 MSCs 改善患者对 COVID-19 的免疫反应的这种新方法，并讨论了这种拟议治疗的各个方面。然而，目前，没有批准的基于 MSCs 的方法用于预防和/或治疗 COVID-19 患者，但正在进行临床试验。
